Exploiting novel molecular targets in gastrointestinal cancers

Wen W. Ma, Manuel Hidalgo

Research output: Contribution to journalArticle

Abstract

Novel molecular targets are being discovered as we learn more about the aberrant processes underlying various cancers. Efforts to translate this knowledge are starting to impact on the care of patients with gastrointestinal cancers. The epidermal growth factor receptor (EGFR) pathway and angiogenesis have been targeted successfully in colorectal cancer with cetuximab, panitunumab and bevacizumab. Similarly, EGFR-targeting with erlotinib yielded significant survival benefit in pancreatic cancer when combined with gemcitabine. The multi-targeting approach with sorafenib has made it the first agent to achieve significant survival benefit in hepatocellular carcinoma. Efforts to exploit the dysregulated Akt/mTOR pathway in GI cancer therapy are ongoing. These molecular targets can be disrupted by various approaches, including the use of monoclonal antibody to intercept extracellular ligands and disrupt receptor-ligand binding, and small molecule inhibitors that interrupt the activation of intracellular kinases.

Original languageEnglish (US)
Pages (from-to)5845-5856
Number of pages12
JournalWorld Journal of Gastroenterology
Volume13
Issue number44
StatePublished - Nov 28 2007

Fingerprint

Gastrointestinal Neoplasms
gemcitabine
Epidermal Growth Factor Receptor
Ligands
Pancreatic Neoplasms
Hepatocellular Carcinoma
Colorectal Neoplasms
Neoplasms
Patient Care
Phosphotransferases
Monoclonal Antibodies
Therapeutics
Bevacizumab
sorafenib
Cetuximab
panitunumab
Erlotinib Hydrochloride

Keywords

  • Angiogenesis
  • Colorectal
  • Epidermal growth factor receptor
  • Liver cancers
  • mTOR
  • Pancreatic
  • Targeted therapy

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Exploiting novel molecular targets in gastrointestinal cancers. / Ma, Wen W.; Hidalgo, Manuel.

In: World Journal of Gastroenterology, Vol. 13, No. 44, 28.11.2007, p. 5845-5856.

Research output: Contribution to journalArticle

Ma, Wen W. ; Hidalgo, Manuel. / Exploiting novel molecular targets in gastrointestinal cancers. In: World Journal of Gastroenterology. 2007 ; Vol. 13, No. 44. pp. 5845-5856.
@article{1e30239c98744c1484168781003b26b7,
title = "Exploiting novel molecular targets in gastrointestinal cancers",
abstract = "Novel molecular targets are being discovered as we learn more about the aberrant processes underlying various cancers. Efforts to translate this knowledge are starting to impact on the care of patients with gastrointestinal cancers. The epidermal growth factor receptor (EGFR) pathway and angiogenesis have been targeted successfully in colorectal cancer with cetuximab, panitunumab and bevacizumab. Similarly, EGFR-targeting with erlotinib yielded significant survival benefit in pancreatic cancer when combined with gemcitabine. The multi-targeting approach with sorafenib has made it the first agent to achieve significant survival benefit in hepatocellular carcinoma. Efforts to exploit the dysregulated Akt/mTOR pathway in GI cancer therapy are ongoing. These molecular targets can be disrupted by various approaches, including the use of monoclonal antibody to intercept extracellular ligands and disrupt receptor-ligand binding, and small molecule inhibitors that interrupt the activation of intracellular kinases.",
keywords = "Angiogenesis, Colorectal, Epidermal growth factor receptor, Liver cancers, mTOR, Pancreatic, Targeted therapy",
author = "Ma, {Wen W.} and Manuel Hidalgo",
year = "2007",
month = "11",
day = "28",
language = "English (US)",
volume = "13",
pages = "5845--5856",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "44",

}

TY - JOUR

T1 - Exploiting novel molecular targets in gastrointestinal cancers

AU - Ma, Wen W.

AU - Hidalgo, Manuel

PY - 2007/11/28

Y1 - 2007/11/28

N2 - Novel molecular targets are being discovered as we learn more about the aberrant processes underlying various cancers. Efforts to translate this knowledge are starting to impact on the care of patients with gastrointestinal cancers. The epidermal growth factor receptor (EGFR) pathway and angiogenesis have been targeted successfully in colorectal cancer with cetuximab, panitunumab and bevacizumab. Similarly, EGFR-targeting with erlotinib yielded significant survival benefit in pancreatic cancer when combined with gemcitabine. The multi-targeting approach with sorafenib has made it the first agent to achieve significant survival benefit in hepatocellular carcinoma. Efforts to exploit the dysregulated Akt/mTOR pathway in GI cancer therapy are ongoing. These molecular targets can be disrupted by various approaches, including the use of monoclonal antibody to intercept extracellular ligands and disrupt receptor-ligand binding, and small molecule inhibitors that interrupt the activation of intracellular kinases.

AB - Novel molecular targets are being discovered as we learn more about the aberrant processes underlying various cancers. Efforts to translate this knowledge are starting to impact on the care of patients with gastrointestinal cancers. The epidermal growth factor receptor (EGFR) pathway and angiogenesis have been targeted successfully in colorectal cancer with cetuximab, panitunumab and bevacizumab. Similarly, EGFR-targeting with erlotinib yielded significant survival benefit in pancreatic cancer when combined with gemcitabine. The multi-targeting approach with sorafenib has made it the first agent to achieve significant survival benefit in hepatocellular carcinoma. Efforts to exploit the dysregulated Akt/mTOR pathway in GI cancer therapy are ongoing. These molecular targets can be disrupted by various approaches, including the use of monoclonal antibody to intercept extracellular ligands and disrupt receptor-ligand binding, and small molecule inhibitors that interrupt the activation of intracellular kinases.

KW - Angiogenesis

KW - Colorectal

KW - Epidermal growth factor receptor

KW - Liver cancers

KW - mTOR

KW - Pancreatic

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=36349031829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36349031829&partnerID=8YFLogxK

M3 - Article

C2 - 17990350

AN - SCOPUS:36349031829

VL - 13

SP - 5845

EP - 5856

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 44

ER -